title: Ischemic colitis associated with paclitaxel.
abstract: Systemic chemotherapy can be complicated by colonic toxicity, which usually determines the onset of pseudomembranous colitis and, rarely, of ischemic colitis in patients with cancer. This report describes the case of a 49-year-old woman with liver metastases from a neuroendocrine tumor of unknown origin who developed mild ischemic colitis after chemotherapy with carboplatin and paclitaxel. The patient developed symptoms of gastrointestinal toxicity with abdominal pain and bloody diarrhea, which resolved in about 10 days. She had a normal white blood cell count throughout her illness; the assay of stool specimens for Clostridium difficile toxins and the stool cultures were both negative. A sigmoidoscopy showed a mild, transient ischemic colitis, which was confirmed by pathologic examination of the biopsy specimens. Although carboplatin is not related to severe colonic cytotoxicity, it has been previously reported that paclitaxel induces necrosis of the gastrointestinal mucosa and inhibits angiogenesis. Pseudomembranous colitis is the most frequent complication in patients with cancer who undergo paclitaxel-based chemotherapy and develop gastrointestinal toxicity. Once C. difficile infection has been excluded, a diagnosis of ischemic colitis should be considered, especially in patients with cancer who have normal white blood cell counts.
authors.affiliation: Department of Medical Oncology, National Cancer Institute and G. Pascale Foundation, Naples, Italy. bdaniele@sirio-oncology.it
authors.forename: B
authors.initials: B
authors.lastname: Daniele
authors.forename: G B
authors.initials: GB
authors.lastname: Rossi
authors.forename: S
authors.initials: S
authors.lastname: Losito
authors.forename: C
authors.initials: C
authors.lastname: Gridelli
authors.forename: M
authors.initials: M
authors.lastname: de Bellis
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001706:Biopsy; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D017091:Colitis, Ischemic / Q000139:chemically induced* / Q000473:pathology; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D007413:Intestinal Mucosa / Q000473:pathology; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary*; D008875:Middle Aged; D009382:Neoplasms, Unknown Primary / Q000188:drug therapy*; D018358:Neuroendocrine Tumors / Q000188:drug therapy / Q000556:secondary*; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects*; D012812:Sigmoidoscopy
chemical_list: D016190:Carboplatin; D017239:Paclitaxel